In 2012, EULAR recommendations for the pharmacological treatment of psoriatic arthritis (PsA) were published (ref). Since then, new treatment strategies and importantly, drugs with new modes of action have been approved for and/or evaluated in PsA.
In 2015, a EULAR Task Force has updated the PsA management recommendations taking into account these new data. A systematic literature review was performed. Subsequently, recommendations were formulated or the previous ones modified based on the literature review and the expert opinion of the 33 Task force members which included 2 patients and 2 health professionals.
The updated recommendations comprise 5 overarching principles and 10 recommendations, covering the pharmacological therapy from non-steroidal anti-inflammatory drugs, through conventional synthetic disease-modifying drugs to biological disease-modifying drugs, whatever their mode of action, taking articular and extraarticular manifestations of PsA into account, but focusing on musculoskeletal involvement.
These recommendations are intended to provide rheumatologists, patients and other stakeholders with an updated consensus on the pharmacological treatment of PsA as well as strategies to reach optimal outcomes in PsA, based on a combination of evidence and expert opinion.
Ref. Gossec L, Smolen JS, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71(1):4-12.
Disclosure of Interest L. Gossec Consultant for: Abbvie, BMS, Celgene, Chugai, Janssen, Novartis, Pfizer, Roche, UCB.